Company Overview
About Orbital Therapeutics
Orbital Therapeutics is a clinical-stage biotechnology company founded in 2022 and headquartered in Cambridge, Massachusetts, with a mission to unlock the full potential of RNA medicines. The company operates at the frontier of RNA biology, advancing a platform that spans circular RNA, self-amplifying RNA, and in vivo CAR-T cell therapies — technologies designed to go beyond the mRNA approaches pioneered during the COVID-19 era. Orbital was co-founded by leading RNA scientists and backed by ARCH Venture Partners, a16z Bio + Health, Newpath Partners, the Abu Dhabi Growth Fund, and Redmile Group, among others.
Business Model & Competitive Advantage
In April 2023, Orbital closed a $270 million Series A financing round to fuel discovery and IND-enabling programs across autoimmune disease, oncology, and inflammatory conditions. By mid-2025, the company publicly disclosed its lead program, OTX-201, an in vivo CAR-T therapy targeting B-cell-mediated autoimmune diseases. Non-human primate data presented at a major conference demonstrated complete B-cell depletion in blood, spleen, and lymph nodes — a requirement for effective immune system reset — setting the stage for a first-in-human clinical trial planned for the first half of 2026.
Competitive Landscape 2025–2026
In 2025, Bristol Myers Squibb announced an agreement to acquire Orbital Therapeutics for approximately $1.5 billion, drawn to the company's in vivo cell therapy approach and its potential to rewire immune systems in people with inflammatory conditions. The acquisition reflects growing Big Pharma conviction in next-generation RNA platforms as an alternative to ex vivo cell therapy, which requires removing, engineering, and re-infusing a patient's own cells. If completed, the deal would make Orbital's circular RNA and in vivo CAR-T technologies part of Bristol Myers Squibb's cell therapy portfolio.
Key Differentiators
Strong Challenger
Orbital Therapeutics is an established challenger with significant market presence and competitive offerings in Life Sciences & BioTech.
Frequently Asked Questions
Similar Brands
Neuralink
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with pa
BioNTech
BioNTech SE was founded in 2008 in Mainz, Germany by Ugur Sahin, Ozlem Tureci, and Christoph Huber with a mission to harness the immune system for individualized cancer treatment. The company pioneere
Illumina
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applicat
Genentech
Genentech was founded in 1976 in South San Francisco by Herbert Boyer and Robert Swanson, becoming the first company to produce human insulin using recombinant DNA technology and essentially launching
Regeneron
Regeneron Pharmaceuticals was founded in 1988 in Tarrytown, New York by Leonard Schleifer and George Yancopoulos. The company built its reputation on the Velocimmune platform—a proprietary humanized m
Pliant Therapeutics
Pliant Therapeutics develops small molecule integrin inhibitors targeting the pathological tissue scarring (fibrosis) that drives diseases including idiopathic pulmonary fibrosis (IPF), primary sclero
Compare Orbital Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Orbital Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Orbital Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Orbital Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →